Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Trojano

Showing results (281-290 of 342) with videos related to

Pageof 35
Sort By:
Plos One|July 7, 2012
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeClaire Meyniel, Timothy Spelman, Vilija G Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 30, 2011
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase RegistryStella Hughes, Timothy Spelman, Maria Trojano, et al.
The Lancet. Neurology|December 26, 2017
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaAlan J Thompson, Brenda L Banwell, Frederik Barkhof, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Brain : a Journal of Neurology|September 16, 2020
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, Mattia Fonderico, Emilio Portaccio, et al.
Neurology|December 21, 2022
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisGiacomo Boffa, Alessio Signori, Luca Massacesi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Journal of Neuroimmunology|October 25, 2003
A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian populationMaria Liguori, Stephen Sawcer, Efrosini Setakis, et al.
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Pageof 35

Showing results (281-290 of 342) with videos related to

Sort By:
Pageof 35
Plos One|July 7, 2012
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeClaire Meyniel, Timothy Spelman, Vilija G Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 30, 2011
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase RegistryStella Hughes, Timothy Spelman, Maria Trojano, et al.
The Lancet. Neurology|December 26, 2017
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaAlan J Thompson, Brenda L Banwell, Frederik Barkhof, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Brain : a Journal of Neurology|September 16, 2020
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, Mattia Fonderico, Emilio Portaccio, et al.
Neurology|December 21, 2022
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisGiacomo Boffa, Alessio Signori, Luca Massacesi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Journal of Neuroimmunology|October 25, 2003
A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian populationMaria Liguori, Stephen Sawcer, Efrosini Setakis, et al.
The Lancet. Neurology|March 22, 2020
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyAnna He, Bernd Merkel, James William L Brown, et al.
Pageof 35